{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:38:29Z","timestamp":1790789909281,"version":"4.1.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T00:00:00Z","timestamp":1650758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00705-022-05432-8","type":"journal-article","created":{"date-parts":[[2022,4,24]],"date-time":"2022-04-24T18:02:35Z","timestamp":1650823355000},"page":"1387-1404","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Viruses as tools in gene therapy, vaccine development, and cancer treatment"],"prefix":"10.1007","volume":"167","author":[{"given":"Musab","family":"bin Umair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujimura Nao","family":"Akusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadia","family":"Kashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Seerat-e-Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marium","family":"Azhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wajeeha","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz","family":"Sharyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Rafique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-5735","authenticated-orcid":false,"given":"Samia","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,24]]},"reference":[{"key":"5432_CR1","doi-asserted-by":"publisher","first-page":"e01386-18","DOI":"10.1128\/JVI.01386-18","volume":"92","author":"S Abdullahi","year":"2018","unstructured":"Abdullahi S, J\u00e4kel M, Behrend SJ, Steiger K, Topping G, Krabbe T, Colombo A, Sandig V, Schiergens TS, Thasler WE, Werner J, Lichtenthaler SF, Schmid RM, Ebert O, Altomonte J (2018) A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma. J Virol 92:e01386-18","journal-title":"J Virol"},{"key":"5432_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.imlet.2017.08.019","volume":"190","author":"SP Ajbani","year":"2017","unstructured":"Ajbani SP, Velhal SM, Kadam RB, Patel VV, Lundstrom K, Bandivdekar AH (2017) Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and polRT genes. Immunol Lett 190:221\u2013232","journal-title":"Immunol Lett"},{"key":"5432_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.7326\/M19-2511","volume":"172","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, La Rosa C, Baden LR, Longmate J, Ariza-Heredia EJ, Rida WN, Lingaraju CR, Zhou Q, Martinez J, Kaltcheva T, Dagis A, Hardwick N, Issa NC, Farol L, Nademanee A, Al Malki MM, Forman S, Nakamura R, Diamond DJ (2020) Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients. Ann Intern Med 172:306\u2013316","journal-title":"Ann Intern Med"},{"key":"5432_CR4","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","volume":"25","author":"NE Annels","year":"2019","unstructured":"Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B (2019) Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res 25:5818\u20135831","journal-title":"Clin Cancer Res"},{"key":"5432_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3390\/v11100914","volume":"11","author":"PS Backhaus","year":"2019","unstructured":"Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyler B, Poth T, J\u00e4ger D, Ungerechts G, Engeland CE (2019) Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists. Viruses 11:914","journal-title":"Viruses"},{"key":"5432_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41541-020-00267-3","volume":"6","author":"MW Bahar","year":"2021","unstructured":"Bahar MW, Porta C, Fox H, Macadam AJ, Fry EE, Stuart DI (2021) Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. npj Vaccines 6:5","journal-title":"npj Vaccines"},{"key":"5432_CR7","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s11262-017-1482-7","volume":"53","author":"SM Bailer","year":"2017","unstructured":"Bailer SM, Funk C, Riedl A, Ruzsics Z (2017) Herpesviral vectors and their application in oncolytic therapy, vaccination, and gene transfer. Virus Genes 53:741\u2013748","journal-title":"Virus Genes"},{"key":"5432_CR8","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/infdis\/170.Supplement_1.S15","volume":"170","author":"WJ Bellini","year":"1994","unstructured":"Bellini WJ, Rota JS, Rota PA (1994) Virology of measles virus. J Infect Dis 170:S15\u2013S23","journal-title":"J Infect Dis"},{"key":"5432_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/v12040451","volume":"12","author":"MB Bello","year":"2020","unstructured":"Bello MB, Yusoff K, Ideris A, Hair-Bejo M, Jibril AH, Peeters BPH, Omar AR (2020) Exploring the prospects of engineered newcastle disease virus in modern vaccinology. Viruses 12:451","journal-title":"Viruses"},{"key":"5432_CR10","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1002\/hep.21437","volume":"44","author":"B Blechacz","year":"2006","unstructured":"Blechacz B, Splinter PL, Greiner S, Myers R, Peng K-W, Federspiel MJ, Russell SJ, LaRusso NF (2006) Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44:1465\u20131477","journal-title":"Hepatology"},{"key":"5432_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.virol.2018.05.028","volume":"521","author":"BS Bodmer","year":"2018","unstructured":"Bodmer BS, Fiedler AH, Hanauer JRH, Pr\u00fcfer S, M\u00fchlebach MD (2018) Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model. Virology 521:99\u2013107","journal-title":"Virology"},{"key":"5432_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s40588-020-00138-4","volume":"7","author":"A Bouin","year":"2020","unstructured":"Bouin A, Semler BL (2020) Picornavirus cellular remodeling: doubling down in response to viral-induced inflammation. Current Clinical Microbiology Reports. 7:31\u201337","journal-title":"Current Clinical Microbiology Reports."},{"key":"5432_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/nyas.14097","volume":"1447","author":"F Broecker","year":"2019","unstructured":"Broecker F, Moelling K (2019) What viruses tell us about evolution and immunity: beyond Darwin? Ann N Y Acad Sci 1447:53","journal-title":"Ann N Y Acad Sci"},{"key":"5432_CR14","doi-asserted-by":"publisher","first-page":"e00015","DOI":"10.1128\/JVI.00015-21","volume":"95","author":"KM Budzik","year":"2021","unstructured":"Budzik KM, Nace RA, Ikeda Y, Russell SJ (2021) Oncolytic foamy virus\u2014generation and properties of a nonpathogenic replicating retroviral vector system that targets chronically proliferating cancer cells. J Virol 95:e00015-21","journal-title":"J Virol"},{"key":"5432_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41434-018-0006-y","volume":"25","author":"C Burkart","year":"2018","unstructured":"Burkart C, Mukhopadhyay A, Shirley SA, Connolly RJ, Wright JH, Bahrami A, Campbell JS, Pierce RH, Canton DA (2018) Improving therapeutic efficacy of IL-12 intratumoral gene electrotransfer through novel plasmid design and modified parameters. Gene Ther 25:93\u2013103","journal-title":"Gene Ther"},{"key":"5432_CR16","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.3390\/cancers12123552","volume":"12","author":"B Burman","year":"2020","unstructured":"Burman B, Pesci G, Zamarin D (2020) Newcastle disease virus at the forefront of cancer immunotherapy. Cancers (Basel) 12:3552","journal-title":"Cancers (Basel)"},{"key":"5432_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1089\/hum.2016.117","volume":"28","author":"PA Campochiaro","year":"2017","unstructured":"Campochiaro PA, Lauer AK, Sohn EH, Mir TA, Naylor S, Anderton MC, Kelleher M, Harrop R, Ellis S, Mitrophanous KA (2017) Lentiviral vector gene transfer of endostatin\/angiostatin for macular degeneration (GEM) study. Hum Gene Ther 28:99\u2013111","journal-title":"Hum Gene Ther"},{"key":"5432_CR18","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1016\/j.vaccine.2009.01.061","volume":"27","author":"G Cantarella","year":"2009","unstructured":"Cantarella G, Liniger M, Zuniga A, Schiller JT, Billeter M, Naim HY, Glueck R (2009) Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 27:3385\u20133390","journal-title":"Vaccine"},{"key":"5432_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/ijms21041433","volume":"21","author":"S-H Chen","year":"2020","unstructured":"Chen S-H, Sun J-M, Chen B-M, Lin S-C, Chang H-F, Collins S, Chang D, Wu S-F, Lu Y-C, Wang W, Chen TC, Kasahara N, Wang H-E, Tai C-K (2020) Efficient prodrug activator gene therapy by retroviral replicating vectors prolongs survival in an immune-competent intracerebral glioma model. Int J Mol Sci 21:1433","journal-title":"Int J Mol Sci"},{"key":"5432_CR20","doi-asserted-by":"publisher","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","volume":"11","author":"F Chiuppesi","year":"2020","unstructured":"Chiuppesi F, Salazar MA, Contreras H, Nguyen VH, Martinez J, Park Y, Nguyen J, Kha M, Iniguez A, Zhou Q, Kaltcheva T, Levytskyy R, Ebelt ND, Kang TH, Wu X, Rogers TF, Manuel ER, Shostak Y, Diamond DJ, Wussow F (2020) Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform. Nat Commun 11:6121","journal-title":"Nat Commun"},{"key":"5432_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41541-021-00303-w","volume":"6","author":"H Cho","year":"2021","unstructured":"Cho H, Jang Y, Park K-H, Choi H, Nowakowska A, Lee H-J, Kim M, Kang M-H, Kim J-H, Shin HY, Oh Y-K, Kim YB (2021) Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2. npj Vaccines 6:37","journal-title":"npj Vaccines"},{"key":"5432_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/10495398.2018.1531014","volume":"31","author":"Y Cho","year":"2020","unstructured":"Cho Y, Heo Y, Choi H, Park KH, Kim S, Jang Y, Lee H-J, Kim M, Kim YB (2020) Porcine endogenous retrovirus envelope coated baculoviral DNA vaccine against porcine reproductive and respiratory syndrome virus. Anim Biotechnol 31:32\u201341","journal-title":"Anim Biotechnol"},{"key":"5432_CR23","doi-asserted-by":"publisher","first-page":"E8547","DOI":"10.1073\/pnas.1805055115","volume":"115","author":"AV Cideciyan","year":"2018","unstructured":"Cideciyan AV, Sudharsan R, Dufour VL, Massengill MT, Iwabe S, Swider M, Lisi B, Sumaroka A, Marinho LF, Appelbaum T, Rossmiller B, Hauswirth WW, Jacobson SG, Lewin AS, Aguirre GD, Beltran WA (2018) Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector. Proc Natl Acad Sci 115:E8547\u2013E8556","journal-title":"Proc Natl Acad Sci"},{"key":"5432_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","volume":"29","author":"L Coughlan","year":"2018","unstructured":"Coughlan L, Sridhar S, Payne R, Edmans M, Milicic A, Venkatraman N, Lugonja B, Clifton L, Qi C, Folegatti PM, Lawrie AM, Roberts R, de Graaf H, Sukhtankar P, Faust SN, Lewis DJM, Lambe T, Hill AVS, Gilbert SC (2018) Heterologous Two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus a in healthy adults. EBioMedicine 29:146\u2013154","journal-title":"EBioMedicine"},{"key":"5432_CR25","doi-asserted-by":"publisher","first-page":"44775","DOI":"10.1038\/srep44775","volume":"7","author":"JR Counsell","year":"2017","unstructured":"Counsell JR, Asgarian Z, Meng J, Ferrer V, Vink CA, Howe SJ, Waddington SN, Thrasher AJ, Muntoni F, Morgan JE, Danos O (2017) Lentiviral vectors can be used for full-length dystrophin gene therapy. Sci Rep 7:44775","journal-title":"Sci Rep"},{"key":"5432_CR26","doi-asserted-by":"crossref","unstructured":"Curti B, Richards J, Hallmeyer S, Faries M, Andtbacka R, Daniels G, Grose M, Shafren DR (2017) Abstract CT114: The MITCI (Phase 1b) study: a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients with or without previous immune checkpoint therapy treatment. 77:CT114","DOI":"10.1158\/1538-7445.AM2017-CT114"},{"key":"5432_CR27","doi-asserted-by":"crossref","unstructured":"Curti BD, Richards JM, Hallmeyer S, Faries MB, Andtbacka RHI, Daniels GA, Grose M, Shafren D (2017) Activity of a novel immunotherapy combination of intralesional Coxsackievirus A21 and systemic ipilimumab in advanced melanoma patients previously treated with anti-PD1 blockade therapy. 35:3014\u20133014","DOI":"10.1200\/JCO.2017.35.15_suppl.3014"},{"key":"5432_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omto.2019.05.001","volume":"14","author":"J Del Papa","year":"2019","unstructured":"Del Papa J, Petryk J, Bell JC, Parks RJ (2019) An oncolytic adenovirus vector expressing p14 FAST protein induces widespread syncytium formation and reduces tumor growth rate in vivo. Mol Ther Oncolytics 14:107\u2013120","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1089\/hum.2019.025","volume":"30","author":"V Dettmer","year":"2019","unstructured":"Dettmer V, Bloom K, Gross M, Weissert K, Aichele P, Ehl S, Cathomen T (2019) Retroviral unc13d gene transfer restores cytotoxic activity of T cells derived from familial hemophagocytic lymphohistiocytosis type 3 patients in vitro. Hum Gene Ther 30:975\u2013984","journal-title":"Hum Gene Ther"},{"key":"5432_CR30","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1126\/science.1123223","volume":"312","author":"T Douglas","year":"2006","unstructured":"Douglas T, Young M (2006) Viruses: making friends with old foes. Science 312:873\u2013875","journal-title":"Science"},{"key":"5432_CR31","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.omto.2020.05.003","volume":"17","author":"NB Elsedawy","year":"2020","unstructured":"Elsedawy NB, Nace RA, Russell SJ, Schulze AJ (2020) Oncolytic activity of targeted picornaviruses formulated as synthetic infectious RNA. Mol Ther Oncolytics 17:484\u2013495","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc9396","volume":"12","author":"H Erasmus Jesse","year":"2020","unstructured":"Erasmus Jesse H, Khandhar Amit P, O\u2019Connor Megan A, Walls Alexandra C, Hemann Emily A, Murapa P, Archer J, Leventhal S, Fuller James T, Lewis Thomas B, Draves Kevin E, Randall S, Guerriero Kathryn A, Duthie Malcolm S, Carter D, Reed Steven G, Hawman David W, Feldmann H, Gale M, Veesler D, Berglund P, Fuller Deborah H (2020) An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci Transl Med. 12:eabc9396","journal-title":"Sci Transl Med."},{"key":"5432_CR33","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","volume":"26","author":"JH Erasmus","year":"2018","unstructured":"Erasmus JH, Khandhar AP, Guderian J, Granger B, Archer J, Archer M, Gage E, Fuerte-Stone J, Larson E, Lin S, Kramer R, Coler RN, Fox CB, Stinchcomb DT, Reed SG, Van Hoeven N (2018) A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against zika. Mol Ther 26:2507\u20132522","journal-title":"Mol Ther"},{"key":"5432_CR34","first-page":"4522","volume":"15","author":"X Fan","year":"2018","unstructured":"Fan X, Lu H, Cui Y, Hou X, Huang C, Liu G (2018) Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway. Exp Ther Med 15:4522\u20134530","journal-title":"Exp Ther Med"},{"key":"5432_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.omtm.2020.03.005","volume":"17","author":"I Fern\u00e1ndez-Fr\u00edas","year":"2020","unstructured":"Fern\u00e1ndez-Fr\u00edas I, P\u00e9rez-Luz S, D\u00edaz-Nido J (2020) Enhanced production of herpes simplex virus 1 amplicon vectors by gene modification and optimization of packaging cell growth medium. Mol Ther Methods Clin Dev 17:491\u2013496","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR36","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1089\/hum.2017.175","volume":"28","author":"F Ferrua","year":"2017","unstructured":"Ferrua F, Aiuti A (2017) Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug. Hum Gene Ther 28:972\u2013981","journal-title":"Hum Gene Ther"},{"key":"5432_CR37","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3389\/fimmu.2020.01959","volume":"11","author":"R F\u00f6rster","year":"2020","unstructured":"F\u00f6rster R, Fleige H, Sutter G (2020) Combating COVID-19: MVA vector vaccines applied to the respiratory tract as promising approach toward protective immunity in the lung. Front Immunol 11:1959","journal-title":"Front Immunol"},{"key":"5432_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.omto.2020.09.007","volume":"19","author":"T Fujiyuki","year":"2020","unstructured":"Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M, Sato H, Hattori S, Yoneda M, Kai C (2020) Recombinant SLAMblind measles virus is a promising candidate for nectin-4-positive triple negative breast cancer therapy. Mol Ther Oncolytics 19:127\u2013135","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fimmu.2018.00171","volume":"9","author":"A Gallinaro","year":"2018","unstructured":"Gallinaro A, Borghi M, Bona R, Grasso F, Calzoletti L, Palladino L, Cecchetti S, Vescio MF, Macchia D, Morante V, Canitano A, Temperton N, Castrucci MR, Salvatore M, Michelini Z, Cara A, Negri D (2018) Integrase defective lentiviral vector as a vaccine platform for delivering influenza antigens. Front Immunol 9:171","journal-title":"Front Immunol"},{"key":"5432_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","volume":"184","author":"K Ganar","year":"2014","unstructured":"Ganar K, Das M, Sinha S, Kumar S (2014) Newcastle disease virus: current status and our understanding. Virus Res 184:71\u201381","journal-title":"Virus Res"},{"key":"5432_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fonc.2019.00297","volume":"9","author":"R Goswami","year":"2019","unstructured":"Goswami R, Subramanian G, Silayeva L, Newkirk I, Doctor D, Chawla K, Chattopadhyay S, Chandra D, Chilukuri N, Betapudi V (2019) Gene therapy leaves a vicious cycle. Front Oncol 9:297","journal-title":"Front Oncol"},{"key":"5432_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-020-02782-6","volume":"11","author":"Y Hagihara","year":"2020","unstructured":"Hagihara Y, Sakamoto A, Tokuda T, Yamashita T, Ikemoto S, Kimura A, Haruta M, Sasagawa K, Ohta J, Takayama K (2020) Photoactivatable oncolytic adenovirus for optogenetic cancer therapy. Cell Death Dis 11:1\u20139","journal-title":"Cell Death Dis"},{"key":"5432_CR43","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.3390\/ijms21228815","volume":"21","author":"BL Hall","year":"2020","unstructured":"Hall BL, Leronni D, Miyagawa Y, Goins WF, Glorioso JC, Cohen JB (2020) Generation of an oncolytic herpes simplex viral vector completely retargeted to the GDNF receptor GFR\u03b11 for specific infection of breast cancer cells. Int J Mol Sci 21:8815","journal-title":"Int J Mol Sci"},{"key":"5432_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100230","volume":"2","author":"AO Hassan","year":"2021","unstructured":"Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huau T-L, Case JB, Meade-White K, Callison J, Chen RE (2021) A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. Cell Rep Med 2:100230","journal-title":"Cell Rep Med"},{"key":"5432_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki O, Dos Santos JM, Hemminki A (2020) Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 13:1\u201315","journal-title":"J Hematol Oncol"},{"key":"5432_CR46","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/neuonc\/nox038","volume":"19","author":"K Hiraoka","year":"2017","unstructured":"Hiraoka K, Inagaki A, Kato Y, Huang TT, Mitchell LA, Kamijima S, Takahashi M, Matsumoto H, Hacke K, Kruse CA, Ostertag D, Robbins JM, Gruber HE, Jolly DJ, Kasahara N (2017) Retroviral replicating vector\u2013mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity. Neuro Oncol 19:918\u2013929","journal-title":"Neuro Oncol"},{"key":"5432_CR47","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/gt.2017.20","volume":"24","author":"D Hoffmann","year":"2017","unstructured":"Hoffmann D, Schott JW, Geis FK, Lange L, M\u00fcller FJ, Lenz D, Zychlinski D, Steinemann D, Morgan M, Moritz T, Schambach A (2017) Detailed comparison of retroviral vectors and promoter configurations for stable and high transgene expression in human induced pluripotent stem cells. Gene Ther 24:298\u2013307","journal-title":"Gene Ther"},{"key":"5432_CR48","doi-asserted-by":"publisher","first-page":"32657","DOI":"10.1073\/pnas.2014468117","volume":"117","author":"C H\u00f6rner","year":"2020","unstructured":"H\u00f6rner C, Sch\u00fcrmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon KH, Scholz T, Herrmann M, Schnierle BS, Baric RS, M\u00fchlebach MD (2020) A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc Natl Acad Sci 117:32657","journal-title":"Proc Natl Acad Sci"},{"key":"5432_CR49","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/biomedicines8030060","volume":"8","author":"A Hromic-Jahjefendic","year":"2020","unstructured":"Hromic-Jahjefendic A, Lundstrom K (2020) Viral vector-based melanoma gene therapy. Biomedicines 8:60","journal-title":"Biomedicines"},{"key":"5432_CR50","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41419-018-0325-3","volume":"9","author":"C Hu","year":"2018","unstructured":"Hu C, Liu Y, Lin Y, Liang J-K, Zhong W-W, Li K, Huang W-T, Wang D-J, Yan G-M, Zhu W-B, Qiu J-G, Gao X (2018) Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer. Cell Death Dis 9:274","journal-title":"Cell Death Dis"},{"key":"5432_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000330","volume":"8","author":"F-Y Huang","year":"2020","unstructured":"Huang F-Y, Wang J-Y, Dai S-Z, Lin Y-Y, Sun Y, Zhang L, Lu Z, Cao R, Tan G-H (2020) A recombinant oncolytic Newcastle virus expressing MIP-3\u03b1 promotes systemic antitumor immunity. J Immunother Cancer 8:e000330","journal-title":"J Immunother Cancer"},{"key":"5432_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.omtm.2017.07.001","volume":"6","author":"S Iizuka","year":"2017","unstructured":"Iizuka S, Sakurai F, Tachibana M, Ohashi K, Mizuguchi H (2017) Neonatal gene therapy for hemophilia B by a novel adenovirus vector showing reduced leaky expression of viral genes. Mol Ther Methods Clin Dev 6:183\u2013193","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR53","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","volume":"13","author":"A Jamali","year":"2019","unstructured":"Jamali A, Kapitza L, Schaser T, Johnston IC, Buchholz CJ, Hartmann J (2019) Highly efficient and selective CAR-gene transfer using CD4-and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev 13:371\u2013379","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR54","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.omtm.2019.03.003","volume":"13","author":"A Jamali","year":"2019","unstructured":"Jamali A, Kapitza L, Schaser T, Johnston ICD, Buchholz CJ, Hartmann J (2019) Highly efficient and selective CAR-gene transfer using CD4- and CD8-targeted lentiviral vectors. Mol Ther Methods Clin Dev 13:371\u2013379","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR55","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.3390\/cancers13061394","volume":"13","author":"J Jazowiecka-Rakus","year":"2021","unstructured":"Jazowiecka-Rakus J, Hadrys A, Rahman MM, McFadden G, Fidyk W, Chmielik E, Pazdzior M, Grajek M, Kozik V, Sochanik A (2021) Myxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinoma. Cancers 13:1394","journal-title":"Cancers"},{"key":"5432_CR56","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1148\/radiol.2018172148","volume":"288","author":"J Ji","year":"2018","unstructured":"Ji J, Weng Q, Zhang F, Xiong F, Jin Y, Hui J, Song J, Gao J, Chen M, Li Q (2018) Non-small-cell lung cancer: feasibility of intratumoral radiofrequency hyperthermia\u2013enhanced herpes simplex virus thymidine kinase gene therapy. Radiology 288:612\u2013620","journal-title":"Radiology"},{"key":"5432_CR57","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","volume":"77","author":"H Jiang","year":"2017","unstructured":"Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB (2017) Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res 77:3894\u20133907","journal-title":"Cancer Res"},{"key":"5432_CR58","first-page":"1089","volume":"165","author":"SY Jin","year":"2020","unstructured":"Jin SY, Jung Y-T (2020) Construction of a replication-competent retroviral vector for expression of the VSV-G envelope glycoprotein for cancer gene therapy. Adv Virol 165:1089\u20131097","journal-title":"Adv Virol"},{"key":"5432_CR59","doi-asserted-by":"publisher","first-page":"e01743-20","DOI":"10.1128\/JVI.01743-20","volume":"95","author":"W-P Jin","year":"2021","unstructured":"Jin W-P, Lu J, Zhang X-Y, Wu J, Wei Z-N, Mai J-Y, Qian S-S, Yu Y-T, Meng S-L, Wang Z-J, Shen S (2021) Efficacy of coxsackievirus A5 vaccine candidates in an actively immunized mouse model. J Virol 95:e01743-20","journal-title":"J Virol"},{"key":"5432_CR60","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1016\/j.vaccine.2020.02.053","volume":"38","author":"DM Johnson","year":"2020","unstructured":"Johnson DM, Jokinen JD, Wang M, Pfeffer T, Tretyakova I, Carrion R, Griffiths A, Pushko P, Lukashevich IS (2020) Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector. Vaccine 38:2949\u20132959","journal-title":"Vaccine"},{"key":"5432_CR61","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/infdis\/jiaa460","volume":"223","author":"E Jordan","year":"2020","unstructured":"Jordan E, Lawrence SJ, Meyer TPH, Schmidt D, Schultz S, Mueller J, Stroukova D, Koenen B, Gruenert R, Silbernagl G, Vidojkovic S, Chen LM, Weidenthaler H, Samy N, Chaplin P (2020) Broad antibody and cellular immune response from a phase 2 clinical trial with a novel multivalent poxvirus-based respiratory syncytial virus vaccine. J Infect Dis 223:1062\u20131072","journal-title":"J Infect Dis"},{"key":"5432_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-030-51927-8_6","volume-title":"Viral vectors in veterinary vaccine development: a textbook","author":"LR Joshi","year":"2021","unstructured":"Joshi LR, Diel DG (2021) Poxvirus vectors. In: Vanniasinkam T, Tikoo SK, Samal SK (eds) Viral vectors in veterinary vaccine development: a textbook. Springer International Publishing, Cham, pp 71\u201394"},{"key":"5432_CR63","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/v9080234","volume":"9","author":"EH Kim","year":"2017","unstructured":"Kim EH, Han G-Y, Nguyen H (2017) An adenovirus-vectored influenza vaccine induces durable cross-protective hemagglutinin stalk antibody responses in mice. Viruses 9:234","journal-title":"Viruses"},{"key":"5432_CR64","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1473-3099(20)30248-6","volume":"20","author":"T Koch","year":"2020","unstructured":"Koch T, Dahlke C, Fathi A, Kupke A, Kr\u00e4hling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM (2020) Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis 20:827\u2013838","journal-title":"Lancet Infect Dis"},{"key":"5432_CR65","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","volume":"26","author":"DB Kohn","year":"2020","unstructured":"Kohn DB, Booth C, Kang EM, Pai S-Y, Shaw KL, Santilli G, Armant M, Buckland KF, Choi U, De Ravin SS, Dorsey MJ, Kuo CY, Leon-Rico D, Rivat C, Izotova N, Gilmour K, Snell K, Dip JX-B, Darwish J, Morris EC, Terrazas D, Wang LD, Bauser CA, Paprotka T, Kuhns DB, Gregg J, Raymond HE, Everett JK, Honnet G, Biasco L, Newburger PE, Bushman FD, Grez M, Gaspar HB, Williams DA, Malech HL, Galy A, Thrasher AJ, Buckland KF, Bauser CA, Honnet G, Grez M, Gaspar HB, Galy A, Thrasher AJ, C.G.D.c. the Net (2020) Lentiviral gene therapy for X-linked chronic granulomatous disease. Nat Med 26:200\u2013206","journal-title":"Nat Med"},{"key":"5432_CR66","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ymthe.2020.11.002","volume":"29","author":"FL Komdeur","year":"2021","unstructured":"Komdeur FL, Singh A, van de Wall S, Meulenberg JJM, Boerma A, Hoogeboom BN, Paijens ST, Oyarce C, de Bruyn M, Schuuring E, Regts J, Marra R, Werner N, Sluis J, van der Zee AGJ, Wilschut JC, Allersma DP, van Zanten CJ, Kosterink JGW, Jorritsma-Smit A, Yigit R, Nijman HW, Daemen T (2021) First-in-human phase I clinical trial of an SFV-based RNA replicon cancer vaccine against HPV-induced cancers. Mol Ther 29:611\u2013625","journal-title":"Mol Ther"},{"key":"5432_CR67","first-page":"483","volume":"163","author":"HR Krishnavajhala","year":"2018","unstructured":"Krishnavajhala HR, Williams J, Heidner H (2018) An influenza A virus vaccine based on an M2e-modified alphavirus. Adv Virol 163:483\u2013488","journal-title":"Adv Virol"},{"key":"5432_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.tim.2009.11.003","volume":"18","author":"DM Kristensen","year":"2010","unstructured":"Kristensen DM, Mushegian AR, Dolja VV, Koonin EV (2010) New dimensions of the virus world discovered through metagenomics. Trends Microbiol 18:11\u201319","journal-title":"Trends Microbiol"},{"key":"5432_CR69","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.chom.2020.12.010","volume":"29","author":"M-W Ku","year":"2021","unstructured":"Ku M-W, Bourgine M, Authi\u00e9 P, Lopez J, Nemirov K, Moncoq F, Noirat A, Vesin B, Nevo F, Blanc C, Souque P, Tabbal H, Simon E, Hardy D, Le Dudal M, Guinet F, Fiette L, Mouquet H, Anna F, Martin A, Escriou N, Majlessi L, Charneau P (2021) Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29:236-249.e236","journal-title":"Cell Host Microbe"},{"key":"5432_CR70","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.virol.2021.04.006","volume":"559","author":"EA Kurt-Jones","year":"2021","unstructured":"Kurt-Jones EA, Dudek TE, Watanabe D, Mandell L, Che J, Zhou S, Cao L, Greenough T, Babcock GJ, Diaz F, Oh HS, Zhou C, Finberg RW, Knipe DM (2021) Expression of SARS coronavirus 1 spike protein from a herpesviral vector induces innate immune signaling and neutralizing antibody responses. Virology 559:165\u2013172","journal-title":"Virology"},{"key":"5432_CR71","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","volume":"3","author":"SE Lawler","year":"2017","unstructured":"Lawler SE, Speranza M-C, Cho C-F, Chiocca EA (2017) Oncolytic viruses in cancer treatment: a review. JAMA Oncol 3:841\u2013849","journal-title":"JAMA Oncol"},{"key":"5432_CR72","doi-asserted-by":"publisher","first-page":"e00363","DOI":"10.1128\/JVI.00363-18","volume":"92","author":"A L\u00e1zaro-Fr\u00edas","year":"2018","unstructured":"L\u00e1zaro-Fr\u00edas A, G\u00f3mez-Medina S, S\u00e1nchez-Sampedro L, Ljungberg K, Ustav M, Liljestr\u00f6m P, Mu\u00f1oz-Fontela C, Esteban M, Garc\u00eda-Arriaza J (2018) Distinct immunogenicity and efficacy of poxvirus-based vaccine candidates against Ebola virus expressing GP and VP40 proteins. J Virol 92:e00363-e1318","journal-title":"J Virol"},{"key":"5432_CR73","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A (2017) Chimpanzee adenovirus vector Ebola vaccine. N Engl J Med 376:928\u2013938","journal-title":"N Engl J Med"},{"key":"5432_CR74","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, Zhao C, Zeng Z, Shu Y, Wu X (2017) Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis 4:43\u201363","journal-title":"Genes Dis"},{"key":"5432_CR75","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jviromet.2019.03.008","volume":"268","author":"ES Lee","year":"2019","unstructured":"Lee ES, Jin SY, Kang BK, Jung Y-T (2019) Construction of replication-competent oncolytic retroviral vectors expressing R peptide-truncated 10A1 envelope glycoprotein. J Virol Methods 268:32\u201336","journal-title":"J Virol Methods"},{"key":"5432_CR76","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.omtm.2018.04.008","volume":"9","author":"C Li","year":"2018","unstructured":"Li C, Psatha N, Gil S, Wang H, Papayannopoulou T, Lieber A (2018) HDAd5\/35++ adenovirus vector expressing anti-CRISPR peptides decreases CRISPR\/Cas9 toxicity in human hematopoietic stem cells. Mol Ther Methods Clin Dev 9:390\u2013401","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR77","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","volume":"36","author":"H Lim","year":"2018","unstructured":"Lim H, In HJ, Lee J-A, Sik Yoo J, Lee S-W, Chung GT, Choi YK, Chung JK, Cho SJ, Lee J-W (2018) The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine 36:3445\u20133452","journal-title":"Vaccine"},{"key":"5432_CR78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-019-1248-6","volume":"570","author":"Y-T Liu","year":"2019","unstructured":"Liu Y-T, Jih J, Dai X, Bi G-Q, Zhou ZH (2019) Cryo-EM structures of herpes simplex virus type 1 portal vertex and packaged genome. Nature 570:257\u2013261","journal-title":"Nature"},{"key":"5432_CR79","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026153118","volume":"118","author":"M Lu","year":"2021","unstructured":"Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O, Kc M, Chaiwatpongsakorn S, Zani A, Kenney A, Zeng C, Cai C, Ye C, Liang X, Shimamura M, Liu S-L, Mejias A, Ramilo O, Boyaka PN, Qiu J, Martinez-Sobrido L, Yount JS, Peeples ME, Kapoor A, Niewiesk S, Li J (2021) A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci 118:e2026153118","journal-title":"Proc Natl Acad Sci"},{"key":"5432_CR80","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1177\/153303460400300508","volume":"3","author":"K Lundstrom","year":"2004","unstructured":"Lundstrom K (2004) Gene therapy applications of viral vectors. Technol Cancer Res Treat 3:467\u2013477","journal-title":"Technol Cancer Res Treat"},{"issue":"Suppl 1","key":"5432_CR81","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1038\/sj.gt.3302620","volume":"12","author":"K Lundstrom","year":"2005","unstructured":"Lundstrom K (2005) Biology and application of alphaviruses in gene therapy. Gene Ther 12(Suppl 1):S92-97","journal-title":"Gene Ther"},{"key":"5432_CR82","first-page":"42","volume":"6","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom K (2018) Viral vectors in gene. Therapy 6:42","journal-title":"Therapy"},{"key":"5432_CR83","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/diseases6020042","volume":"6","author":"K Lundstrom","year":"2018","unstructured":"Lundstrom K (2018) Viral vectors in gene therapy. Diseases 6:42","journal-title":"Diseases"},{"key":"5432_CR84","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/genes10030189","volume":"10","author":"K Lundstrom","year":"2019","unstructured":"Lundstrom K (2019) RNA viruses as tools in gene therapy and vaccine development. Genes (Basel). 10:189","journal-title":"Genes (Basel)."},{"key":"5432_CR85","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.3390\/ijms21145130","volume":"21","author":"K Lundstrom","year":"2020","unstructured":"Lundstrom K (2020) Self-amplifying RNA viruses as RNA vaccines. Int J Mol Sci 21:5130","journal-title":"Int J Mol Sci"},{"key":"5432_CR86","doi-asserted-by":"publisher","first-page":"317","DOI":"10.3390\/v13020317","volume":"13","author":"K Lundstrom","year":"2021","unstructured":"Lundstrom K (2021) Viral vectors for COVID-19 vaccine development. Viruses 13:317","journal-title":"Viruses"},{"key":"5432_CR87","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/vco.12547","volume":"18","author":"AL MacNeill","year":"2020","unstructured":"MacNeill AL (2020) The potential of the combined use of targeted type I interferon pathway inhibitors and oncolytic viruses to treat sarcomas. Vet Comp Oncol 18:36\u201342","journal-title":"Vet Comp Oncol"},{"key":"5432_CR88","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.21037\/tlcr-20-547","volume":"9","author":"M Maemondo","year":"2020","unstructured":"Maemondo M (2020) Perspective of gene therapy with replication competent viruses. Transl Lung Cancer Res. 9:2511\u20132513","journal-title":"Transl Lung Cancer Res."},{"key":"5432_CR89","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2018-99-119591","volume":"132","author":"P Malik","year":"2018","unstructured":"Malik P, Grimley M, Quinn CT, Shova A, Courtney L, Lutzko C, Kalfa TA, Niss O, Mehta PA, Chandra S, Grassman E, Van der Loo JCM, Witting S, Nordling D, Shreshta A, Felker S, Terrell C, Reeves L, Pillis D, Anastacia L, Bushman FD, Knight-Madden J, Kalinyak K, Davies SM, Asnani M (2018) Gene therapy for sickle cell anemia using a modified gamma globin lentivirus vector and reduced intensity conditioning transplant shows promising correction of the disease phenotype. Blood 132:1021","journal-title":"Blood"},{"key":"5432_CR90","doi-asserted-by":"publisher","first-page":"8952","DOI":"10.1038\/s41598-018-27433-x","volume":"8","author":"VK Manoharan","year":"2018","unstructured":"Manoharan VK, Khattar SK, LaBranche CC, Montefiori DC, Samal SK (2018) Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus. Sci Rep 8:8952","journal-title":"Sci Rep"},{"key":"5432_CR91","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.omto.2021.03.008","volume":"21","author":"M Martikainen","year":"2021","unstructured":"Martikainen M, Ramachandran M, Lugano R, Ma J, Martikainen M-M, Dimberg A, Yu D, Merits A, Essand M (2021) IFN-I-tolerant oncolytic Semliki Forest virus in combination with anti-PD1 enhances T cell response against mouse glioma. Mol Ther Oncolytics 21:37\u201346","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR92","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bjc.2017.151","volume":"117","author":"M Martikainen","year":"2017","unstructured":"Martikainen M, Ruotsalainen J, Tuomela J, H\u00e4rk\u00f6nen P, Essand M, Heikkil\u00e4 J, Hinkkanen A (2017) Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice. Br J Cancer 117:51\u201355","journal-title":"Br J Cancer"},{"key":"5432_CR93","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3389\/fimmu.2020.00449","volume":"11","author":"JM Martinez-Navio","year":"2020","unstructured":"Martinez-Navio JM, Fuchs SP, Mendes DE, Rakasz EG, Gao G, Lifson JD, Desrosiers RC (2020) Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front Immunol 11:449\u2013449","journal-title":"Front Immunol"},{"key":"5432_CR94","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3390\/cancers11050685","volume":"11","author":"C McCarthy","year":"2019","unstructured":"McCarthy C, Jayawardena N, Burga LN, Bostina M (2019) Developing picornaviruses for cancer therapy. Cancers 11:685","journal-title":"Cancers"},{"key":"5432_CR95","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","volume":"11","author":"PF McKay","year":"2020","unstructured":"McKay PF, Hu K, Blakney AK, Samnuan K, Brown JC, Penn R, Zhou J, Bouton CR, Rogers P, Polra K, Lin PJC, Barbosa C, Tam YK, Barclay WS, Shattock RJ (2020) Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat Commun 11:3523","journal-title":"Nat Commun"},{"key":"5432_CR96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/gt.2017.55","volume":"24","author":"A Meidahl","year":"2017","unstructured":"Meidahl A, Klukinov M, Tzabazis A, Sorensen J, Yeomans D (2017) Nasal application of HSV encoding human preproenkephalin blocks craniofacial pain in a rat model of traumatic brain injury. Gene Ther 24:482\u2013486","journal-title":"Gene Ther"},{"key":"5432_CR97","doi-asserted-by":"publisher","first-page":"eaav7325","DOI":"10.1126\/scitranslmed.aav7325","volume":"11","author":"M Milani","year":"2019","unstructured":"Milani M, Annoni A, Moalli F, Liu T, Cesana D, Calabria A, Bartolaccini S, Biffi M, Russo F, Visigalli I (2019) Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates. Sci Transl Med 11:eaav7325","journal-title":"Sci Transl Med"},{"key":"5432_CR98","doi-asserted-by":"publisher","first-page":"13999","DOI":"10.1038\/s41598-019-50222-z","volume":"9","author":"Z Mohamed Amin","year":"2019","unstructured":"Mohamed Amin Z, Che Ani MA, Tan SW, Yeap SK, Alitheen NB, Syed Najmuddin SUF, Kalyanasundram J, Chan SC, Veerakumarasivam A, Chia SL, Yusoff K (2019) Evaluation of a recombinant newcastle disease virus expressing human IL12 against human breast cancer. Sci Rep 9:13999","journal-title":"Sci Rep"},{"key":"5432_CR99","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/v13020355","volume":"13","author":"V Morante","year":"2021","unstructured":"Morante V, Borghi M, Farina I, Michelini Z, Grasso F, Gallinaro A, Cecchetti S, Di Virgilio A, Canitano A, Pirillo MF, Bona R, Cara A, Negri D (2021) Integrase-defective lentiviral vector is an efficient vaccine platform for cancer immunotherapy. Viruses 13:355","journal-title":"Viruses"},{"key":"5432_CR100","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41467-019-13939-z","volume":"11","author":"MM Mosaheb","year":"2020","unstructured":"Mosaheb MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M (2020) Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun 11:524","journal-title":"Nat Commun"},{"key":"5432_CR101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009283","volume":"17","author":"M\u00c1 Mu\u00f1oz-Al\u00eda","year":"2021","unstructured":"Mu\u00f1oz-Al\u00eda M\u00c1, Nace RA, Tischer A, Zhang L, Bah ES, Auton M, Russell SJ (2021) MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. PLoS Pathog 17:e1009283","journal-title":"PLoS Pathog"},{"key":"5432_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-017-0029-1","volume":"2","author":"VJ Munster","year":"2017","unstructured":"Munster VJ, Wells D, Lambe T, Wright D, Fischer RJ, Bushmaker T, Saturday G, Van Doremalen N, Gilbert SC, De Wit E (2017) Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. npj Vaccines 2:1\u20134","journal-title":"npj Vaccines"},{"key":"5432_CR103","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4161\/hv.34298","volume":"11","author":"HY Naim","year":"2015","unstructured":"Naim HY (2015) Measles virus. Hum Vaccines Immunother 11:21\u201326","journal-title":"Hum Vaccines Immunother"},{"key":"5432_CR104","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9761","volume":"8","author":"SUFS Najmuddin","year":"2020","unstructured":"Najmuddin SUFS, Amin ZM, Tan SW, Yeap SK, Kalyanasundram J, Veerakumarasivam A, Chan SC, Chia SL, Yusoff K, Alitheen NBJP (2020) Oncolytic effects of the recombinant Newcastle disease virus, rAF-IL12, against colon cancer cells in vitro and in tumor-challenged NCr-Foxn1nu nude mice. PeerJ 8:e9761","journal-title":"PeerJ"},{"key":"5432_CR105","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","volume":"31","author":"MF Naso","year":"2017","unstructured":"Naso MF, Tomkowicz B, Perry WL, Strohl WR (2017) Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs 31:317\u2013334","journal-title":"BioDrugs"},{"key":"5432_CR106","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1016\/j.vaccine.2019.11.088","volume":"38","author":"B Nath","year":"2020","unstructured":"Nath B, Vandna HM, Saini MP, Kumar S (2020) Evaluation of Japanese encephalitis virus E and NS1 proteins immunogenicity using a recombinant Newcastle disease virus in mice. Vaccine 38:1860\u20131868","journal-title":"Vaccine"},{"key":"5432_CR107","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1161\/CIRCRESAHA.118.313811","volume":"124","author":"L Ni","year":"2019","unstructured":"Ni L, Scott L, Campbell HM, Pan X, Alsina KM, Reynolds J, Philippen LE, Hulsurkar M, Lagor WR, Li N, Wehrens XHT (2019) Atrial-specific gene delivery using an adeno-associated viral vector. Circ Res 124:256\u2013262","journal-title":"Circ Res"},{"key":"5432_CR108","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ymthe.2019.03.008","volume":"27","author":"TD Norton","year":"2019","unstructured":"Norton TD, Zhen A, Tada T, Kim J, Kitchen S, Landau NR (2019) Lentiviral vector-based dendritic cell vaccine suppresses HIV replication in humanized mice. Mol Ther 27:960\u2013973","journal-title":"Mol Ther"},{"key":"5432_CR109","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01485-18","volume":"93","author":"C N\u00fcrnberger","year":"2019","unstructured":"N\u00fcrnberger C, Bodmer Bianca S, Fiedler Anna H, Gabriel G, M\u00fchlebach Michael D, Heise Mark T (2019) A measles virus-based vaccine candidate mediates protection against zika virus in an allogeneic mouse pregnancy model. J Virol 93:e01485","journal-title":"J Virol"},{"key":"5432_CR110","doi-asserted-by":"publisher","first-page":"12459","DOI":"10.1038\/s41598-018-31003-6","volume":"8","author":"P \u00d6hlund","year":"2018","unstructured":"\u00d6hlund P, Garc\u00eda-Arriaza J, Zusinaite E, Szurgot I, M\u00e4nnik A, Kraus A, Ustav M, Merits A, Esteban M, Liljestr\u00f6m P, Ljungberg K (2018) DNA-launched RNA replicon vaccines induce potent anti-Ebolavirus immune responses that can be further improved by a recombinant MVA boost. Sci Rep 8:12459","journal-title":"Sci Rep"},{"key":"5432_CR111","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","volume":"34","author":"N Packiriswamy","year":"2020","unstructured":"Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, Rooney CM, Dispenzieri A, Peng K-W, Russell SJ (2020) Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34:3310\u20133322","journal-title":"Leukemia"},{"key":"5432_CR112","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/B978-0-12-384964-9.00005-0","volume-title":"Challenges in delivery of therapeutic genomics and proteomics","author":"DH Patel","year":"2011","unstructured":"Patel DH, Misra A (2011) 5\u2014gene delivery using viral vectors. In: Misra A (ed) Challenges in delivery of therapeutic genomics and proteomics. Elsevier, London, pp 207\u2013270"},{"key":"5432_CR113","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.omto.2019.06.004","volume":"14","author":"A Pelin","year":"2019","unstructured":"Pelin A, Foloppe J, Petryk J, Singaravelu R, Hussein M, Gossart F, Jennings VA, Stubbert LJ, Foster M, Storbeck C, Postigo A, Scut E, Laight B, Way M, Erbs P, Le Boeuf F, Bell JC (2019) Deletion of apoptosis inhibitor F1L in vaccinia virus increases safety and oncolysis for cancer therapy. Mol Ther Oncolytics 14:246\u2013252","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR114","doi-asserted-by":"publisher","first-page":"e01230","DOI":"10.1128\/JVI.01230-17","volume":"91","author":"F Pitoiset","year":"2017","unstructured":"Pitoiset F, Vazquez T, Levacher B, Nehar-Belaid D, D\u00e9rian N, Vigneron J, Klatzmann D, Bellier B, Simon V (2017) Retrovirus-based virus-like particle immunogenicity and its modulation by toll-like receptor activation. J Virol 91:e01230-e11217","journal-title":"J Virol"},{"key":"5432_CR115","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.ymthe.2020.02.016","volume":"28","author":"CE Porter","year":"2020","unstructured":"Porter CE, Shaw AR, Jung Y, Yip T, Castro PD, Sandulache VC, Sikora A, Gottschalk S, Ittman MM, Brenner MK (2020) Oncolytic adenovirus armed with BiTE, cytokine, and checkpoint inhibitor enables CAR T cells to control the growth of heterogeneous tumors. Mol Ther 28:1251\u20131262","journal-title":"Mol Ther"},{"key":"5432_CR116","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy FH, Lewis DJ, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C, Hare J, Cox JH, Dally L, Bendel D (2019) Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV 6:e230\u2013e239","journal-title":"Lancet HIV"},{"key":"5432_CR117","doi-asserted-by":"publisher","first-page":"15710","DOI":"10.1038\/s41598-017-15941-1","volume":"7","author":"MM Rahman","year":"2017","unstructured":"Rahman MM, Bagdassarian E, Ali MAM, McFadden G (2017) Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells. Sci Rep 7:15710","journal-title":"Sci Rep"},{"key":"5432_CR118","first-page":"171","volume":"9","author":"MM Rahman","year":"2020","unstructured":"Rahman MM, McFadden G (2020) Oncolytic virotherapy with myxoma. Virus 9:171","journal-title":"Virus"},{"key":"5432_CR119","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fonc.2019.00052","volume":"9","author":"J Reul","year":"2019","unstructured":"Reul J, Frisch J, Engeland CE, Thalheimer FB, Hartmann J, Ungerechts G, Buchholz CJ (2019) Tumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectors. Front Oncol 9:52","journal-title":"Front Oncol"},{"key":"5432_CR120","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3389\/fphar.2021.682299","volume":"12","author":"N Reyne","year":"2021","unstructured":"Reyne N, Cmielewski P, McCarron A, Delhove J, Parsons D, Donnelley M (2021) Single-dose lentiviral mediated gene therapy recovers CFTR function in cystic fibrosis knockout rats. Front Pharmacol 12:1204","journal-title":"Front Pharmacol"},{"key":"5432_CR121","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","volume":"18","author":"M Robert-Guroff","year":"2007","unstructured":"Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18:546\u2013556","journal-title":"Curr Opin Biotechnol"},{"key":"5432_CR122","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3390\/vaccines8030472","volume":"8","author":"MA Rohaim","year":"2020","unstructured":"Rohaim MA, Munir M (2020) A scalable topical vectored vaccine candidate against SARS-CoV-2. Vaccines 8:472","journal-title":"Vaccines"},{"key":"5432_CR123","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1038\/s41598-019-40071-1","volume":"9","author":"A Rossi","year":"2019","unstructured":"Rossi A, Dupaty L, Aillot L, Zhang L, Gallien C, Hallek M, Odenthal M, Adriouch S, Salvetti A, B\u00fcning H (2019) Vector uncoating limits adeno-associated viral vector-mediated transduction of human dendritic cells and vector immunogenicity. Sci Rep 9:3631","journal-title":"Sci Rep"},{"key":"5432_CR124","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/infdis\/jiz202","volume":"220","author":"SL Rossi","year":"2019","unstructured":"Rossi SL, Comer JE, Wang E, Azar SR, Lawrence WS, Plante JA, Ramsauer K, Schrauf S, Weaver SC (2019) Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates. J Infect Dis 220:735\u2013742","journal-title":"J Infect Dis"},{"key":"5432_CR125","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jviromet.2018.02.020","volume":"256","author":"RP Rota","year":"2018","unstructured":"Rota RP, Palacios CA, Temprana CF, Arg\u00fcelles MH, Mandile MG, Mattion N, Laimbacher AS, Fraefel C, Castello AA, Glikmann G (2018) Evaluation of the immunogenicity of a recombinant HSV-1 vector expressing human group C rotavirus VP6 protein. J Virol Methods 256:24\u201331","journal-title":"J Virol Methods"},{"key":"5432_CR126","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.3390\/v6093563","volume":"6","author":"B Saha","year":"2014","unstructured":"Saha B, Wong CM, Parks RJ (2014) The adenovirus genome contributes to the structural stability of the virion. Viruses 6:3563\u20133583","journal-title":"Viruses"},{"key":"5432_CR127","first-page":"687","volume":"52","author":"N Sato","year":"2018","unstructured":"Sato N, Saga Y, Uchibori R, Tsukahara T, Urabe M, Kume A, Fujiwara H, Suzuki M, Ozawa K, Mizukami H (2018) Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6\/E7. Int J Oncol 52:687\u2013696","journal-title":"Int J Oncol"},{"key":"5432_CR128","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/biomedicines7030066","volume":"7","author":"V Schirrmacher","year":"2019","unstructured":"Schirrmacher V, van Gool S, Stuecker W (2019) Breaking therapy resistance: an update on oncolytic newcastle disease virus for improvements of cancer therapy. Biomedicines 7:66","journal-title":"Biomedicines"},{"key":"5432_CR129","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1089\/hgtb.2016.188","volume":"28","author":"M Schn\u00f6dt","year":"2017","unstructured":"Schn\u00f6dt M, B\u00fcning H (2017) Improving the quality of adeno-associated viral vector preparations: the challenge of product-related impurities. Hum Gene Ther Methods 28:101\u2013108","journal-title":"Hum Gene Ther Methods"},{"key":"5432_CR130","doi-asserted-by":"crossref","unstructured":"Sheridan C (2015) First oncolytic virus edges towards approval in surprise vote. Nature Publishing Group","DOI":"10.1038\/nbt0615-569"},{"key":"5432_CR131","doi-asserted-by":"publisher","first-page":"19307","DOI":"10.1038\/s41598-020-76449-9","volume":"10","author":"CM Siegrist","year":"2020","unstructured":"Siegrist CM, Kinahan SM, Settecerri T, Greene AC, Santarpia JL (2020) CRISPR\/Cas9 as an antiviral against Orthopoxviruses using an AAV vector. Sci Rep 10:19307","journal-title":"Sci Rep"},{"key":"5432_CR132","doi-asserted-by":"publisher","first-page":"CT026","DOI":"10.1158\/1538-7445.AM2017-CT026","volume":"77","author":"AW Silk","year":"2017","unstructured":"Silk AW, Kaufman H, Gabrail N, Mehnert J, Bryan J, Norrell J, Medina D, Bommareddy P, Shafren D, Grose M, Zloza A (2017) Phase 1b study of intratumoral Coxsackievirus A21 (CVA21) and systemic pembrolizumab in advanced melanoma patients: Interim results of the CAPRA clinical trial. Cancer Res 77:CT026","journal-title":"Cancer Res"},{"key":"5432_CR133","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1016\/j.vaccine.2019.08.017","volume":"37","author":"T Sitt","year":"2019","unstructured":"Sitt T, Kenney M, Barrera J, Pandya M, Eckstrom K, Warner M, Pacheco JM, LaRocco M, Palarea-Albaladejo J, Brake D (2019) Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers. Vaccine 37:6221\u20136231","journal-title":"Vaccine"},{"key":"5432_CR134","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13568-019-0741-5","volume":"9","author":"HR Soares","year":"2019","unstructured":"Soares HR, Castro R, Tom\u00e1s HA, Carrondo MJT, Alves PM, Coroadinha AS (2019) Pseudotyping retrovirus like particles vaccine candidates with Hepatitis C virus envelope protein E2 requires the cellular expression of CD81. AMB Express 9:22","journal-title":"AMB Express"},{"key":"5432_CR135","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005958","volume":"11","author":"B Stading","year":"2017","unstructured":"Stading B, Ellison JA, Carson WC, Satheshkumar PS, Rocke TE, Osorio JE (2017) Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine. PLOS Negl Trop Dis 11:e0005958","journal-title":"PLOS Negl Trop Dis"},{"key":"5432_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205139","volume":"13","author":"KE Stephenson","year":"2018","unstructured":"Stephenson KE, Keefer MC, Bunce CA, Frances D, Abbink P, Maxfield LF, Neubauer GH, Nkolola J, Peter L, Lane C (2018) First-in-human randomized controlled trial of an oral, replicating adenovirus 26 vector vaccine for HIV-1. PLoS ONE 13:e0205139","journal-title":"PLoS ONE"},{"key":"5432_CR137","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","volume":"58","author":"JH Strauss","year":"1994","unstructured":"Strauss JH, Strauss EG (1994) The alphaviruses: gene expression, replication, and evolution. Microbiol Rev 58:491\u2013562","journal-title":"Microbiol Rev"},{"key":"5432_CR138","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/1078-0432.CCR-16-2900","volume":"23","author":"KA Streby","year":"2017","unstructured":"Streby KA, Geller JI, Currier MA, Warren PS, Racadio JM, Towbin AJ, Vaughan MR, Triplet M, Ott-Napier K, Dishman DJ (2017) Intratumoral injection of HSV1716, an oncolytic herpes virus, is safe and shows evidence of immune response and viral replication in young cancer patients. Clin Cancer Res 23:3566\u20133574","journal-title":"Clin Cancer Res"},{"key":"5432_CR139","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pathogens9121001","volume":"9","author":"J Struzik","year":"2020","unstructured":"Struzik J, Szulc-D\u0105browska L (2020) NF-\u03baB as an important factor in optimizing poxvirus-based vaccines against viral infections. Pathogens 9:1001","journal-title":"Pathogens"},{"key":"5432_CR140","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.omto.2017.05.005","volume":"6","author":"AW Studebaker","year":"2017","unstructured":"Studebaker AW, Hutzen BJ, Pierson CR, Haworth KB, Cripe TP, Jackson EM, Leonard JR (2017) Oncolytic herpes virus rRp450 shows efficacy in orthotopic xenograft group 3\/4 medulloblastomas and atypical teratoid\/rhabdoid tumors. Mol Ther Oncolytics 6:22\u201330","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR141","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.omto.2020.03.022","volume":"17","author":"K Sugawara","year":"2020","unstructured":"Sugawara K, Iwai M, Yajima S, Tanaka M, Yanagihara K, Seto Y, Todo T (2020) Efficacy of a third-generation oncolytic herpes virus g47\u03b4 in advanced stage models of human gastric cancer. Mol Ther Oncolytics 17:205\u2013215","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103132","volume":"62","author":"W Sun","year":"2020","unstructured":"Sun W, Leist SR, McCroskery S, Liu Y, Slamanig S, Oliva J, Amanat F, Sch\u00e4fer A, Dinnon KH III, Garc\u00eda-Sastre A, Krammer F, Baric RS, Palese P (2020) Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine 62:103132","journal-title":"EBioMedicine"},{"key":"5432_CR143","doi-asserted-by":"publisher","first-page":"18571","DOI":"10.1073\/pnas.1906653116","volume":"116","author":"K Suwan","year":"2019","unstructured":"Suwan K, Yata T, Waramit S, Przystal JM, Stoneham CA, Bentayebi K, Asavarut P, Chongchai A, Pothachareon P, Lee K-Y, Topanurak S, Smith TL, Gelovani JG, Sidman RL, Pasqualini R, Arap W, Hajitou A (2019) Next-generation of targeted AAVP vectors for systemic transgene delivery against cancer. Proc Natl Acad Sci 116:18571\u201318577","journal-title":"Proc Natl Acad Sci"},{"key":"5432_CR144","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12032-017-1034-y","volume":"34","author":"M Takamura-Ishii","year":"2017","unstructured":"Takamura-Ishii M, Miura T, Nakaya T, Hagiwara K (2017) Induction of antitumor response to fibrosarcoma by Newcastle disease virus-infected tumor vaccine. Med Oncol 34:171","journal-title":"Med Oncol"},{"key":"5432_CR145","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1038\/s41467-019-11687-8","volume":"10","author":"F Tan","year":"2019","unstructured":"Tan F, Chu C, Qi J, Li W, You D, Li K, Chen X, Zhao W, Cheng C, Liu X, Qiao Y, Su B, He S, Zhong C, Li H, Chai R, Zhong G (2019) AAV-ie enables safe and efficient gene transfer to inner ear cells. Nat Commun 10:3733","journal-title":"Nat Commun"},{"key":"5432_CR146","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1146\/annurev.genet.33.1.133","volume":"33","author":"H Tang","year":"1999","unstructured":"Tang H, Kuhen KL, Wong-Staal F (1999) Lentivirus replication and regulation. Annu Rev Genet 33:133\u2013170","journal-title":"Annu Rev Genet"},{"key":"5432_CR147","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1473-3099(20)30019-0","volume":"20","author":"MD Tapia","year":"2020","unstructured":"Tapia MD, Sow SO, Mbaye KD, Thiongane A, Ndiaye BP, Ndour CT, Mboup S, Keshinro B, Kinge TN, Vernet G, Bigna JJ, Oguche S, Koram KA, Asante KP, Gobert P, Hogrefe WR, De Ryck I, Debois M, Bourguignon P, Jongert E, Ballou WR, Koutsoukos M, Roman F, Amusu S, Ayuk L, Bilong C, Boahen O, Camara M, Cheick Haidara F, Coly D, Di\u00e8ye S, Dosoo D, Ekedi M, I. Eneida Almeida Dos Santos, S. Kaali, A. Kokogho, M. Levine, N. Opoku, S. Owusu-Agyei, S. Pitmang, F. Sall, M. Seydi, M. Sztein, M. Tejiokem, A. Traore, M.-A. Vernet, and A.K. Yawson. (2020) Safety, reactogenicity, and immunogenicity of a chimpanzee adenovirus vectored Ebola vaccine in children in Africa: a randomised, observer-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 20:719\u2013730","journal-title":"Lancet Infect Dis"},{"key":"5432_CR148","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.virol.2016.06.006","volume":"496","author":"TJ Taylor","year":"2016","unstructured":"Taylor TJ, Diaz F, Colgrove RC, Bernard KA, DeLuca NA, Whelan SP, Knipe DM (2016) Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector. Virology 496:186\u2013193","journal-title":"Virology"},{"key":"5432_CR149","unstructured":"Terry M (2020) Two patient deaths halt Audentes\u2019 gene therapy trial"},{"key":"5432_CR150","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1016\/j.vaccine.2020.02.007","volume":"38","author":"I Tretyakova","year":"2020","unstructured":"Tretyakova I, Plante KS, Rossi SL, Lawrence WS, Peel JE, Gudjohnsen S, Wang E, Mirchandani D, Tibbens A, Lamichhane TN, Lukashevich IS, Comer JE, Weaver SC, Pushko P (2020) Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge. Vaccine 38:3378\u20133386","journal-title":"Vaccine"},{"key":"5432_CR151","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1016\/j.vaccine.2019.04.072","volume":"37","author":"I Tretyakova","year":"2019","unstructured":"Tretyakova I, Tibbens A, Jokinen JD, Johnson DM, Lukashevich IS, Pushko P (2019) Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome. Vaccine 37:3317\u20133325","journal-title":"Vaccine"},{"key":"5432_CR152","doi-asserted-by":"publisher","first-page":"e02308","DOI":"10.1128\/JVI.02308-18","volume":"93","author":"Y-H Tsai","year":"2019","unstructured":"Tsai Y-H, Huang S-W, Hsieh W-S, Cheng C-K, Chang C-F, Wang Y-F, Wang J-R (2019) Enterovirus A71 containing codon-deoptimized VP1 and high-fidelity polymerase as next-generation vaccine candidate. J Virol 93:e02308-02318","journal-title":"J Virol"},{"key":"5432_CR153","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1487913","volume":"7","author":"S van de Wall","year":"2018","unstructured":"van de Wall S, Ljungberg K, Ip PP, Boerma A, Knudsen ML, Nijman HW, Liljestr\u00f6m P, Daemen T (2018) Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens. OncoImmunology. 7:e1487913","journal-title":"OncoImmunology."},{"key":"5432_CR154","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.omtm.2019.06.002","volume":"14","author":"FT van den Berg","year":"2019","unstructured":"van den Berg FT, Makoah NA, Ali SA, Scott TA, Mapengo RE, Mutsvunguma LZ, Mkhize NN, Lambson BE, Kgagudi PD, Crowther C, Abdool Karim SS, Balazs AB, Weinberg MS, Ely A, Arbuthnot PB, Morris L (2019) AAV-mediated expression of broadly neutralizing and vaccine-like antibodies targeting the HIV-1 envelope V2 region. Mol Ther Methods Clin Dev 14:100\u2013112","journal-title":"Mol Ther Methods Clin Dev"},{"key":"5432_CR155","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/infdis\/jix644","volume":"217","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout LP, Soule G, Sorensen D, Frost KL, He S, Tierney K, Safronetz D, Booth SA, Kobinger GP, Qiu X, Wootton SK (2018) Intramuscular adeno-associated virus-mediated expression of monoclonal antibodies provides 100% protection against ebola virus infection in mice. J Infect Dis 217:916\u2013925","journal-title":"J Infect Dis"},{"issue":"1","key":"5432_CR156","first-page":"1","volume":"36","author":"L Vannucci","year":"2013","unstructured":"Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M (2013) Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 36(1):1\u201322","journal-title":"New Microbiol"},{"key":"5432_CR157","doi-asserted-by":"publisher","first-page":"6208","DOI":"10.1016\/j.vaccine.2017.09.028","volume":"35","author":"N Venkatraman","year":"2017","unstructured":"Venkatraman N, Anagnostou N, Bliss C, Bowyer G, Wright D, L\u00f6vgren-Bengtsson K, Roberts R, Poulton I, Lawrie A, Ewer K (2017) Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M\u2122. Vaccine 35:6208\u20136217","journal-title":"Vaccine"},{"key":"5432_CR158","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/jgm.2993","volume":"19","author":"M Ventosa","year":"2017","unstructured":"Ventosa M, Wu Z, Lim F (2017) Sustained FXN expression in dorsal root ganglia from a nonreplicative genomic HSV-1 vector. J Gene Med 19:376\u2013386","journal-title":"J Gene Med"},{"key":"5432_CR159","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-01635-1","volume":"7","author":"G Verlengia","year":"2017","unstructured":"Verlengia G, Miyagawa Y, Ingusci S, Cohen JB, Simonato M, Glorioso JC (2017) Engineered HSV vector achieves safe long-term transgene expression in the central nervous system. Sci Rep 7:1\u201311","journal-title":"Sci Rep"},{"key":"5432_CR160","doi-asserted-by":"publisher","first-page":"e01677","DOI":"10.1128\/JVI.01677-19","volume":"94","author":"G Vijayakumar","year":"2020","unstructured":"Vijayakumar G, McCroskery S, Palese P (2020) Engineering newcastle disease virus as an oncolytic vector for intratumoral delivery of immune checkpoint inhibitors and immunocytokines. J Virol 94:e01677-e11619","journal-title":"J Virol"},{"key":"5432_CR161","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","volume":"49","author":"G Vijayakumar","year":"2019","unstructured":"Vijayakumar G, Palese P, Goff PH (2019) Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine 49:96\u2013105","journal-title":"EBioMedicine"},{"key":"5432_CR162","doi-asserted-by":"publisher","first-page":"e00976","DOI":"10.1128\/JVI.00976-18","volume":"92","author":"EG Viktorova","year":"2018","unstructured":"Viktorova EG, Khattar SK, Kouiavskaia D, Laassri M, Zagorodnyaya T, Dragunsky E, Samal S, Chumakov K, Belov GA (2018) Newcastle disease virus-based vectored vaccine against poliomyelitis. J Virol 92:e00976-e1918","journal-title":"J Virol"},{"key":"5432_CR163","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1089\/cbr.2019.3084","volume":"36","author":"J Wang","year":"2021","unstructured":"Wang J, Liu T, Chen J (2021) Oncolytic measles virus encoding interleukin-12 mediated antitumor activity and immunologic control of colon cancer in vivo and ex vivo. Cancer Biother Radiopharm 36:774\u2013782","journal-title":"Cancer Biother Radiopharm"},{"key":"5432_CR164","first-page":"1539","volume":"18","author":"J Wang","year":"2019","unstructured":"Wang J, Sun M, Zhu X, Zhao H, Mao D, Zhang Z, Zhao X (2019) Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice. Oncol Lett 18:1539\u20131547","journal-title":"Oncol Lett"},{"key":"5432_CR165","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.vaccine.2017.12.046","volume":"36","author":"M Wang","year":"2018","unstructured":"Wang M, Jokinen J, Tretyakova I, Pushko P, Lukashevich IS (2018) Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins. Vaccine 36:683\u2013690","journal-title":"Vaccine"},{"key":"5432_CR166","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41434-019-0058-7","volume":"26","author":"Q Wang","year":"2019","unstructured":"Wang Q, Vossen A, Ikeda Y, Devaux P (2019) Measles vector as a multigene delivery platform facilitating iPSC reprogramming. Gene Ther 26:151\u2013164","journal-title":"Gene Ther"},{"key":"5432_CR167","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.3389\/fmicb.2018.02943","volume":"9","author":"Y Wang","year":"2018","unstructured":"Wang Y, Ma L, Stipkovits L, Szathmary S, Li X, Liu Y (2018) The strategy of picornavirus evading host antiviral responses: non-structural proteins suppress the production of IFNs. Front Microbiol 9:2943","journal-title":"Front Microbiol"},{"key":"5432_CR168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"S Wu","year":"2020","unstructured":"Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y (2020) A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:1\u20137","journal-title":"Nat Commun"},{"key":"5432_CR169","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejphar.2017.02.042","volume":"802","author":"Y Wu","year":"2017","unstructured":"Wu Y, He J, Geng J, An Y, Ye X, Yan S, Yu Q, Yin J, Zhang Z, Li D (2017) Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy. Eur J Pharmacol 802:85\u201392","journal-title":"Eur J Pharmacol"},{"key":"5432_CR170","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1186\/s13046-019-1410-x","volume":"38","author":"M Xia","year":"2019","unstructured":"Xia M, Luo D, Dong J, Zheng M, Meng G, Wu J, Wei J (2019) Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy. J Exp Clin Cancer Res 38:408","journal-title":"J Exp Clin Cancer Res"},{"key":"5432_CR171","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/cas.13468","volume":"109","author":"X Xu","year":"2018","unstructured":"Xu X, Sun Q, Mei Y, Liu Y, Zhao L (2018) Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer Sci 109:279\u2013288","journal-title":"Cancer Sci"},{"key":"5432_CR172","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.virusres.2017.03.003","volume":"233","author":"X Xu","year":"2017","unstructured":"Xu X, Sun Q, Yu X, Zhao L (2017) Rescue of nonlytic newcastle disease virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Res 233:35\u201341","journal-title":"Virus Res"},{"key":"5432_CR173","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.omto.2019.06.001","volume":"14","author":"X Xu","year":"2019","unstructured":"Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, Zhao L (2019) Tumor cells modified with newcastle disease virus expressing IL-24 as a cancer vaccine. Mol Ther Oncolytics 14:213\u2013221","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR174","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.omto.2017.12.001","volume":"8","author":"K Yagiz","year":"2018","unstructured":"Yagiz K, Rodriguez-Aguirre ME, Lopez Espinoza F, Montellano TT, Mendoza D, Mitchell LA, Ibanez CE, Kasahara N, Gruber HE, Jolly DJ, Robbins JM (2018) A retroviral replicating vector encoding cytosine deaminase and 5-FC induces immune memory in metastatic colorectal cancer models. Mol Ther Oncolytics 8:14\u201326","journal-title":"Mol Ther Oncolytics"},{"key":"5432_CR175","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.4103\/0366-6999.209909","volume":"130","author":"M-L Yang","year":"2017","unstructured":"Yang M-L, Tao T, Xu J, Liu Z, Xu D (2017) Antiapoptotic effect of gene therapy with recombinant adenovirus vector containing hypoxia-inducible factor-1\u03b1 after cerebral ischemia and reperfusion in rats. Chin Med J (Engl) 130:1700\u20131706","journal-title":"Chin Med J (Engl)"},{"key":"5432_CR176","doi-asserted-by":"publisher","first-page":"5520","DOI":"10.1038\/s41598-019-42004-4","volume":"9","author":"A Yoshida","year":"2019","unstructured":"Yoshida A, Kim S-H, Manoharan VK, Varghese BP, Paldurai A, Samal SK (2019) Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs. Sci Rep 9:5520","journal-title":"Sci Rep"},{"key":"5432_CR177","unstructured":"Zabaleta N, Dai W, Bhatt U, Chichester JA, Sanmiguel J, Estelien R, Michalson KT, Diop C, Maciorowski D, Qi W, Hudspeth E, Cucalon A, Dyer CD, Pampena MB, Knox JJ, LaRocque RC, Charles RC, Li D, Kim M, Sheridan A, Storm N, Johnson RI, Feldman J, Hauser BM, Ryan A, Zinn E, Kobayashi DT, Chauhan R, McGlynn M, Ryan ET, Schmidt AG, Price B, Honko A, Griffiths A, Yaghmour S, Hodge R, Betts MR, Freeman MW, Wilson JM, Vandenberghe LH (2021) An AAV-based, room-temperature stable, single dose COVID-19 vaccine. bioRxiv:2021.2001.2005.422952"},{"key":"5432_CR178","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"F-C Zhu","year":"2020","unstructured":"Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395:1845\u20131854","journal-title":"Lancet"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05432-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-022-05432-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-022-05432-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T23:39:09Z","timestamp":1744155549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-022-05432-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,24]]},"references-count":178,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["5432"],"URL":"https:\/\/doi.org\/10.1007\/s00705-022-05432-8","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,24]]},"assertion":[{"value":"22 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}